Clinical Trial Update: FUSCC Refractory TNBC Platform Study (FUTURE2.0) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update for the FUTURE2.0 platform study at Fudan University in refractory triple-negative breast cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Snippet

Sponsor: Fudan University | Conditions: Triple-negative Breast Cancer | Phase 2 | Status: RECRUITING